China takes another stride in the area of science and technology by establishing its 4th research station – ‘Taishan’ – in Antarctica after Kunlun, Zhongshan and Great Wall. Meant to be a summer-only station, It will contribute in research on bio-ecology and remote satellite sensing. Moreover, China is also looking for a site for another (5th) research station.
It’s a type of blood disorder which affects the body’s ability to produce hemoglobin and red blood cells. In this disease, patient has less number of red blood cells in their bodies and having less hemoglobin as compared to normal human beings. It results in to development of anemia and fatigue. Thalassemia is caused by variant or missing genes that affect how the body makes hemoglobin. It is a hereditary disease.
IMPORTANT WORDS, BEFORE READING THIS ARTICLE
⇒ International Telecommunication Union (ITU):
The International Telecommunication Union (ITU), originally founded as the International Telegraph Union, is a specialized agency of the United Nations that is responsible for issues that concern information and communication technologies. The ITU coordinates the shared global use of the radio spectrum, promotes international cooperation in assigning satellite orbits, works to improve telecommunication infrastructure in the developing world, and assists in the development and coordination of worldwide technical standards. It is based in Geneva, Switzerland.
India’s largest ever warship – the INS Vikramaditya – has been finally commissioned into Indian Navy after a nine year refit and refurbish programme at the North Russian shipyard of Sevmash at Severodvinsk.
- The ship, expected to reach India by the end of January 2014, is supposed to sail through three oceans and several seas to its home Karwar naval base, Karnataka (India).
- The 284-metre long carrier is to be flanked by the frigate INS Trikhand and fleet tanker INS Deepak on its way home. Both will join the warship at the Northwest Russian port of Murmansk.
After a decade of research in an endeavor to develop a drug for Lung Cancer, Cadila Pharmaceuticals today launched its DCGI approved ‘Mycidac–C’, a first-of-its-kind drug which will be used in the treatment of Non Small Cell Lung Cancer (NSCLC).
According to WHO, approximately 1.25 million people are diagnosed with Lung Cancer every year globally, and around 30% of them suffer from squamous NSCLC.
Dr T Ramasami, Secretary to the Government of India, Department of Science and Technology commented, “Lung cancer is a major killer among all cancers. In this scenario, Mycidac-C is a new hope for patients suffering form lung cancer, particularly for Indian patients.”
This new drug is a first-in-class active immunotherapy, as well as a drug targeting Desmocollin-3. According to Cadila, there has been no significant innovation in the management of squamous NSCLC ever since the introduction of platinum containing doublet in 1983. However, Mycidac-C has to be used with platinum containing doublet therapy.